| Literature DB >> 24634838 |
Sarkar M A Kawsar1, Md O Faruk1, Mohammad S Rahman2, Yuki Fujii3, Yasuhiro Ozeki4.
Abstract
A regioselective acylation series of methyl α-D-glucopyranoside (1), methyl 3-O-benzoyl-4,6-O-benzylidene-α-D-mannopyranoside (1A), and methyl 4,6-O-benzylidene-2-O-(3,5-dinitrobenzoyl)-α-D-mannopyranoside (1B) has been carried out by the direct acylation method and afforded the 2,6-di-O-glucopyranoside and 2 or 3-O-mannopyranoside derivatives in an excellent yield. In order to obtain newer products, the 2,6-di-O-glucopyranoside derivative was further transformed to a series of 3,4-di-O-acyl derivatives containing a wide variety of functionalities in a single molecular framework. The structures of the newly synthesized compounds were elucidated on the basis of IR, (1)H-NMR, (13)C-NMR, (13)C-DEPT spectral data, and elemental analysis. These synthesized derivatives were screened for in vitro antimicrobial activities against ten human pathogenic and five phytopathogenic microorganisms. A number of test compounds showed remarkable antimicrobial activity comparable to, and in some cases even higher than, the standard antibiotics employed. It was observed that methyl 3,4-di-O-(3-chlorobenzoyl)-2,6-di-O-hexanoyl-α-D-glucopyranoside (8) exhibited a varied range of MIC from 12.5 μg/disc to 25 μg/disc by the disk diffusion method and 1000 μg/mL to 1250 μg/mL by the broth macrodilution method.Entities:
Keywords: Antimicrobial; Derivatives; Elucidation; Glucopyranosides; Spectroscopy; Synthesis
Year: 2013 PMID: 24634838 PMCID: PMC3951222 DOI: 10.3797/scipharm.1308-03
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Sch. 1Synthesis of D-glucopyranoside derivatives (2–9).
Sch. 2Synthesis of D-mannopyranoside derivatives (10–14).
Antibacterial screening studies against Gram-positive bacteria by (2–14).
| Compound | Diameter of zone of inhibition in mm 200 μg dw/disc | |||
|---|---|---|---|---|
|
| ||||
| 2 | 9 | 8 | 11 | |
| 3 | NF | NF | NF | NF |
| 4 | NF | NF | NF | NF |
| 5 | 7.5 | 6.5 | 12 | 10 |
| 6 | NF | NF | NF | NF |
| 7 | 14 | 14 | 10 | 12 |
| 8 | ||||
| 9 | NF | NF | NF | NF |
| 10 | NF | NF | NF | NF |
| 11 | NF | NF | NF | NF |
| 12 | NF | NF | NF | NF |
| 13 | NF | NF | NF | NF |
| 14 | 7.5 | NF | 6 | |
= marked inhibition;
= standard antibiotic;
NF = not found; dw = dry weight.
Antibacterial screening studies against Gram-negative bacteria of tested compounds (2–14).
| Compound | Diameter of zone of inhibition in mm 200 μg dw/disc | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| INABAET | ||||||
| 2 | 20 | 11 | 19 | 11.5 | 7 | 7.5 |
| 3 | NF | NF | NF | NF | NF | NF |
| 4 | NF | NF | NF | NF | NF | NF |
| 5 | 10 | 7.5 | 9 | 8.5 | 6.5 | 7.5 |
| 6 | NF | NF | NF | NF | NF | NF |
| 7 | 16 | 11.5 | 8 | 15 | NF | 12 |
| 8 | 28 | 25 | 25 | 22 | 21 | 28 |
| 9 | NF | NF | NF | NF | NF | NF |
| 10 | NF | NF | NF | NF | NF | NF |
| 11 | NF | NF | NF | NF | NF | NF |
| 12 | NF | NF | NF | NF | NF | NF |
| 13 | NF | NF | NF | NF | NF | NF |
| 14 | 18 | 7.5 | 9 | 7.5 | 8 | 8 |
= marked inhibition;
= standard antibiotic;
NF = not found; dw = dry weight.
Fig. 1Zone of inhibition against B. cereus (A) and S. typhi (B) by the compounds 6–9.
MIC test of compound 8 against ten human pathogenic bacteria by disk diffusion method.
| Test Bacteria | Diameter of zone of inhibition in mm | MIC μg/disc | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 300 μg/disc | 150 μg/disc | 100 μg/disc | 50 μg/disc | 25 μg/disc | 12.5 μg/disc | 6.25 μg/disc | ||
| 20 | 16 | 14 | 10 | 8 | NF | NF | 25 | |
| 26 | 20 | 18 | 12 | 10 | 8 | NF | 12.5 | |
| 28 | 19 | 15 | 12 | 10 | 8 | NF | 12.5 | |
| 27 | 20 | 15 | 11 | 10 | 8 | NF | 12.5 | |
| 20 | 15 | 13 | 9 | 7 | NF | NF | 12.5 | |
| 28 | 20 | 18 | 14 | 9 | 7.5 | NF | 12.5 | |
| 25 | 15 | 14 | 11 | 8 | NF | NF | 25 | |
| 25 | 19 | 17 | 10 | 8 | NF | NF | 25 | |
| 22 | 17 | 13 | 10 | 8 | NF | NF | 25 | |
| INABAET ( | 28 | 20 | 18 | 14 | 10 | 8 | NF | 12.5 |
MIC test of compound 8 against ten human pathogenic bacteria by broth macrodilution method.
| Test Bacteria | Growth in peptone broth/extract concentration (μg/mL) | MIC μg/mL | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 125 | 250 | 500 | 750 | 1000 | 1250 | 1500 | ||
| + | + | + | + | + | − | − | 1250 | |
| + | + | + | + | − | − | − | 1000 | |
| + | + | + | + | − | − | − | 1000 | |
| + | + | + | + | − | − | − | 1000 | |
| + | + | + | + | + | − | − | 1250 | |
| + | + | + | + | + | − | − | 1250 | |
| + | + | + | + | + | − | − | 1250 | |
| + | + | + | + | + | − | − | 1250 | |
| + | + | + | + | + | − | − | 1250 | |
| INABAET ( | + | + | + | + | − | − | − | 1000 |
(+) indicate positive and (−) indicate negative.
Antifungal activities of the test chemicals (2–14).
| Compound | Inhibition % of fungal mycelial growth | ||||
|---|---|---|---|---|---|
|
| |||||
| 2 | 30 | 20 | 25 | 25 | 30 |
| 3 | 25 | 40 | 10 | 20 | 22 |
| 4 | 25 | 12 | 18 | 15 | 15 |
| 5 | 34 | 36 | 25 | 30 | 35 |
| 6 | 10 | NF | 17 | 12 | NF |
| 7 | 40 | 35 | 30 | 40 | 35 |
| 8 | |||||
| 9 | 30 | NF | 9 | NF | 9 |
| 10 | NF | NF | NF | 10 | NF |
| 11 | NF | 16 | 12 | 15 | 10 |
| 12 | NF | NF | NF | NF | NF |
| 13 | NF | NF | NF | 8 | NF |
| 14 | 25 | 35 | 15 | 20 | 15 |
= marked inhibition;
= standard antibiotic;
NF = not found; dw = dry weight;
= growth measured-radial in cm.
Fig. 2% Inhibition of mycelial growth against A: F. equiseti and B: M. phaseolina by compound 8.
MIC test of compound 8 against five phytopathogenic fungi.
| Test Fungi | Growth in sabouroud/extract concentration (μg/mL) | MIC μg/mL | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 31.25 | 62.5 | 125 | 250 | 500 | 750 | 1000 | ||
| + | + | + | − | − | − | − | 250 | |
| + | + | + | − | − | − | − | 250 | |
| + | − | − | − | − | − | − | 62.5 | |
| + | − | − | − | − | − | − | 62.5 | |
| + | + | − | − | − | − | − | 125 | |
(+) indicate positive and (−) indicate negative.